The Food and Drug Administration and announced on Friday that it would postpone authorization of Pfizer’s Covid vaccine for children under the age of five, and instead wait for results from Pfizer’s clinical trials to include a third vaccine dose for young children.
The FDA said in a statement that it is delaying a vaccine advisory-panel meeting, initially scheduled for Tuesday, meant to debate authorization of the Pfizer vaccine for the age group.
“Based on the agency’s preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization,” read the statement.
Children in Pfizer’s clinical trials have received one-tenth the Covid vaccine dosage given to adults. The vaccine did not produce the desired amount of antibodies in children ages 2-4 but did in those younger than two, while no safety concerns were identified, multiple officials told the New York Times.
Source: National Review
